| Biological Sciences | Lifetime | 543 | SG 2 | 99.93 |
| Biological Sciences | 2021-2025 | 274 | SG 1 | 99.73 |
| Molecular Medicine | Lifetime | 3 | SG 1 | 99.93 |
| Applied Microbiology and Biotechnology | Lifetime | 2 | SG 1 | 99.72 |
| Infectious Diseases | Lifetime | 111 | SG 2 | 99.65 |
| Clinical Pharmacology | Lifetime | 116 | SG 2 | 99.51 |
| Epidemiology | Lifetime | 341 | SG 3 | 99.58 |
| Clinical Biochemistry | Lifetime | 73 | SG 1 | 98.42 |
| Endocrinology | Lifetime | 99 | SG 2 | 98.61 |
| Critical Care and Intensive Care Medicine | Lifetime | 271 | SG 1 | 94.59 |
| Molecular Medicine | 2021-2025 | 6 | SG 1 | 99.48 |
| Clinical Biochemistry | 2021-2025 | 4 | SG 1 | 98.03 |
| Applied Microbiology and Biotechnology | 2021-2025 | 5 | SG 1 | 98.48 |
| Epidemiology | 2021-2025 | 270 | SG 3 | 97.83 |
| Clinical Pharmacology | 2021-2025 | 109 | SG 4 | 96.35 |
| Infectious Diseases | 2021-2025 | 379 | SG 3 | 92.60 |
| Antibiotic Resistance in Bacteria | Lifetime | 4 | SG 1 | 99.98 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 3 | SG 1 | 99.96 |
| Antibiotic Use and Resistance | Lifetime | 3 | SG 1 | 99.97 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 6 | SG 1 | 99.89 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 3 | SG 1 | 99.79 |
| Vibrio bacteria research studies | Lifetime | 33 | SG 3 | 99.60 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 53 | SG 1 | 99.64 |
| Urinary Tract Infections Management | Lifetime | 48 | SG 1 | 99.45 |
| Pneumonia and Respiratory Infections | Lifetime | 107 | SG 1 | 99.51 |
| Nosocomial Infections in ICU | Lifetime | 39 | SG 1 | 99.55 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 139 | SG 1 | 99.25 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 132 | SG 1 | 99.08 |
| Antifungal resistance and susceptibility | Lifetime | 213 | SG 2 | 98.74 |
| Bacterial biofilms and quorum sensing | Lifetime | 275 | SG 4 | 98.33 |
| Mycobacterium research and diagnosis | Lifetime | 551 | SG 4 | 97.41 |
| Infections and bacterial resistance | Lifetime | 48 | SG 1 | 97.34 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 577 | SG 1 | 97.84 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 358 | SG 2 | 97.33 |
| Streptococcal Infections and Treatments | Lifetime | 636 | SG 1 | 96.80 |
| Fungal Infections and Studies | Lifetime | 618 | SG 2 | 96.31 |
| Escherichia coli research studies | Lifetime | 839 | SG 4 | 94.36 |
| Infection Control in Healthcare | Lifetime | 445 | SG 4 | 89.79 |
| Neurological Complications and Syndromes | Lifetime | 920 | SG 5 | 88.06 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 5 | SG 1 | 99.79 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 2 | SG 1 | 99.79 |
| Antibiotic Use and Resistance | 2021-2025 | 3 | SG 1 | 99.73 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 3 | SG 1 | 99.72 |
| Pneumonia and Respiratory Infections | 2021-2025 | 85 | SG 1 | 97.48 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 77 | SG 1 | 96.04 |
| Infective Endocarditis Diagnosis and Management | 2021-2025 | 262 | SG 1 | 96.65 |
| Streptococcal Infections and Treatments | 2021-2025 | 126 | SG 1 | 93.20 |
| Urinary Tract Infections Management | 2021-2025 | 157 | SG 1 | 92.32 |
| Infections and bacterial resistance | 2021-2025 | 47 | SG 2 | 85.41 |
| Antifungal resistance and susceptibility | 2021-2025 | 898 | SG 7 | 85.08 |
| Nosocomial Infections in ICU | 2021-2025 | 724 | SG 5 | 71.87 |
